Quince Therapeutics (QNCX) Operating Income (2018 - 2026)
Quince Therapeutics (QNCX) posted quarterly Operating Income of -$14.6 million for Q1 2026, up 1.8% year-over-year from -$14.3 million in Q1 2025, and up 24.61% quarter-over-quarter from -$19.4 million in Q4 2025.
Quince Therapeutics (QNCX) Operating Income (2018 - 2026) Analysis & Trends
Quince Therapeutics' Operating Income history runs 9 years deep, the most recent figure standing at -$14.6 million for Q1 2026.
- In Q1 2026, Operating Income rose 1.8% year-over-year to -$14.6 million; the TTM figure through Mar 2026 stood at -$57.8 million (up 5.13% YoY), while the FY2025 annual figure was -$58.1 million, down 1.37% from the prior year.
- Operating Income for Q1 2026 stood at -$14.6 million, up from -$19.4 million in the prior quarter.
- The five-year high for Operating Income was -$5.6 million in Q2 2023, with the low at -$28.2 million in Q2 2024.
- The 5-year median for Operating Income is -$12.0 million (2024), against an average of -$12.7 million.
- The sharpest annual moves came in 2022 and 2024: Operating Income jumped 73.16% in 2022, then slumped 404.87% in 2024.
- Quince Therapeutics' Operating Income stood at -$6.3 million in 2022, then sank by 57.0% to -$9.9 million in 2023, then slipped by 21.08% to -$12.0 million in 2024, then plunged by 61.11% to -$19.4 million in 2025, then increased by 24.61% to -$14.6 million in 2026.
- Business Quant data shows QNCX's Operating Income at -$14.6 million in Q1 2026, -$19.4 million in Q4 2025, and -$13.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | 133.12 Mn |
| 10 | Quince Therapeutics | 200.91 Mn | 200.91 Mn | - | -79.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.59 Mn |
| Dec 31, 2025 | -19.35 Mn |
| Sep 30, 2025 | -13.43 Mn |
| Jun 30, 2025 | -10.43 Mn |
| Mar 31, 2025 | -14.86 Mn |
| Dec 31, 2024 | -12.01 Mn |
| Sep 30, 2024 | -5.86 Mn |
| Jun 30, 2024 | -28.19 Mn |
| Mar 31, 2024 | -11.22 Mn |
| Dec 31, 2023 | -9.92 Mn |
| Sep 30, 2023 | -6.09 Mn |
| Jun 30, 2023 | -5.58 Mn |
| Mar 31, 2023 | -12.96 Mn |
| Dec 31, 2022 | -6.32 Mn |
| Sep 30, 2022 | -7.62 Mn |
| Jun 30, 2022 | -16.26 Mn |
| Mar 31, 2022 | -21.86 Mn |
| Dec 31, 2021 | -23.54 Mn |
| Sep 30, 2021 | -21.68 Mn |
| Jun 30, 2021 | -21.78 Mn |